STAT+ subscribers can sign up here to get it delivered to their inbox. As we count down toward the December readout of ...

Cassava Sciences Inc. (NASDAQ: SAVA) is a biotech developing treatments for Alzheimer's disease. The company has a lot of ...

Cassava Sciences, Inc. (SAVA) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting ...

Cassava Sciences' stock is highly shorted, with potential reward tied to the upcoming Phase 3 trial results for simufilam.

U.S. markets have been on a historic bull run since the end of the pandemic. However, many investors may start to be wary.

Cassava Sciences ( (SAVA) ) has released its Q3 earnings. Here is a breakdown of the information Cassava Sciences presented to its investors.

Cassava Sciences' RETHINK-ALZ trial is nearing data release. See why SAVA stock could see volatility depending on trial ...

In terms of valuation, Cassava Sciences Inc’s market capitalization stands at $1.29 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s ...

Top-line Data for RETHINK-ALZ 52-week Phase 3 trial Expected Before the End of 2024 $149.0 Million in Cash and Cash ...

BioSpace takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.

Today, Benzinga's options scanner spotted 8 options trades for Cassava Sciences. This isn't normal. The overall sentiment of ...

Today, Benzinga 's options scanner spotted 11 uncommon options trades for Cassava Sciences. This isn't normal. The overall ...